Blue Oak Pharmaceuticals has partnered with PGI Drug Discovery (PsychoGenics) to optimise new treatments for brain and psychiatric disorders.

The deal allows access to PsychoGenics’ phenotypic discovery platforms such as SmartCube system and its expertise in machine learning for the discovery of therapeutics from Blue Oak’s chemotypes library.

In addition to wide in-vivo behavioural expertise, PsychoGenics platforms involve robotics, computer vision and bioinformatics designed for assessment of potential drug candidates in various CNS disease indications.

Blue Oak Pharmaceuticals president and CEO Tom Large said: “We have a strong, ten-year relationship with Dr Emer Leahy and PsychoGenics that has validated our systems neurobiology paradigm for discovering clinical molecules with mechanisms-of-action distinct from existing drugs.

“We are confident that combining PGI’s deep behavioural profiling with Blue Oak’s privileged chemotypes and brain imaging biomarkers will yield the new therapies that have eluded the industry for several decades.”

“We are confident that combining PGI’s deep behavioural profiling with Blue Oak’s privileged chemotypes and brain imaging biomarkers will yield the new therapies that have eluded the industry for several decades.””

Blue Oak designed its chemistry platform to engage brain circuits through polypharmacology and integrates brain imaging with translational medicine biomarkers for quick optimisation of clinical leads.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PsychoGenics uses machine learning to analyse high-dimensional behavioural data for the phenotypical identification of treatments with new mechanisms of action.

The firm has already discovered a psychotropic agent that is currently under evaluation in Phase II clinical trials for the treatment of schizophrenia and Parkinson’s disease psychosis.

PsychoGenics president and CEO Emer Leahy said: “We have worked productively together at Sunovion in the past and have every confidence we can again discover first-in-class drugs and ultimately deliver much-needed treatments to patients with severely disabling psychiatric conditions.”